• Mashup Score: 0
    How can venetoclax combinations improve outcome for FLT3-mutant AML? - 2 year(s) ago

    During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax combinations improve outcome for FLT3-mutant AML?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      📹 During #ASH2021 the #AMLHub was pleased to speak with @Daver_Leukemia, @MDAndersonNews. We asked, How can venetoclax combinations improve outcome for FLT3-mutant #AML? 👉 https://t.co/YdYexGlstR 👈 #AMLsm #leusm #leukemia https://t.co/zR0FIs34PZ

  • Mashup Score: 1
    What factors should be considered when selecting treatment for an elderly AML patient? - 2 year(s) ago

    During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What factors should be considered when selecting treatment for an elderly AML patient?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      📹During #ASH2021, the #AMLHub was pleased to speak with @UwePlatzbecker, @UniLeipzig. We asked, What factors should be considered when selecting treatment for an elderly #AML patient? 👉 https://t.co/JpJn8omG0V 👈 #AMLsm #leusm #leukemia https://t.co/mcsCPj6ozq

  • Mashup Score: 4
    MRD in AML: Prognosis, treatment, and surrogate endpoints - 2 year(s) ago

    In recent years, the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) has been established, and early evidence suggests that MRD analysis may help to guide and personalize treatment decisions.

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🔎At the #LLMCongress2021, @RolandBWalter, @fredhutch, provided an update on the status of MRD in the acute myeloid #leukemia setting. 👀 Take a look at the #AMLHub summary here: 👉 https://t.co/C0Y8a0J6Yl 👈 #AML #leusm

  • Mashup Score: 1
    A new method for developing a consensus guideline in AML - 2 year(s) ago

    The AML Hub was pleased to speak with Tom Coats, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. We asked, What is the new method for developing a consensus guideline in AML.

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      📹 The #AMLHub spoke with Tom Coats, @RDEhospitals. We asked, What is the new method for developing a consensus guideline in #AML? 👉 https://t.co/eg5srZqTIs 👈 #leusm #leukemia https://t.co/tuEEKmRcZf

  • Mashup Score: 1
    How do you incorporate MRD into treatment decision-making in clinical practice? - 2 year(s) ago

    During Lymphoma, Leukemia & Myeloma Congress 2021, the AML Hub was pleased to speak to Koen van Besien, NewYork-Presbyterian Hospital, New York, US. We asked, How do you incorporate measurable residual disease (MRD) into treatment decision-making in clinical practice?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      📹During #LLMCongress2021, the #AMLHub was pleased to speak to @kvbesien, @nyphospital. We asked, How do you incorporate MRD into treatment decision-making in clinical practice? 👉 https://t.co/hKlCsdbe1y 👈 #leusm #AMLsm #AML #leukemia https://t.co/OiDkOut0C5

  • Mashup Score: 1
    How efficacious is CAR-T in childhood AML? - 2 year(s) ago

    During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children’s Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      ⏰ Catch up with this! 👀 During #ASCO21, the #AMLHub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center. We asked, How efficacious is CAR-T in childhood #AML? 👉 https://t.co/sFJYUh36TN 👈 #leusm #amlsm #leukemia #pedonc https://t.co/Bh5egq28tW

  • Mashup Score: 1
    How does pre-transplant MRD affect outcome in AML? - 2 year(s) ago

    During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does pre-transplant measurable residual disease (MRD) affect outcome in AML?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      📹 Missed this video? During EHA2021 The #AMLHub spoke with @nagler_EBMT, @TelAvivUni. We asked, how does pre-transplant #MRD affect outcome in #AML? 👉 https://t.co/NDQjKQ1X7A 👈 #AMLsm #leukemia #leusm

  • Mashup Score: 1
    How can venetoclax combinations be used in preparation for transplant? - 2 year(s) ago

    During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax combinations be used in preparation for transplant? Lachowiez begins by giving background on venetoclax and recent studies around it.

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      💉 During #ASH2021, the #AMLHub was pleased to speak with @CLachowiez, @MDAndersonNews. We asked, How can venetoclax combinations be used in preparation for transplant? 👉 https://t.co/0mlTnAZSBO 👈 #leusm #leukemia #AMLsm

Load More